Intraoperative Blood Loss Under Standard Versus Low Pneumoperitoneum Pressure During Laparoscopic Liver Resection.

NCT ID: NCT06060899

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-01

Study Completion Date

2024-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Commonly the pressure of about 14 mmHg is applied during laparoscopic liver resection (LLR) with moderate neuromuscular blockade. Lowering the pneumoperitoneum pressure combined with deep neuromuscular blockade may sustain optimal operating space with providing better short-term postoperative results. It has been proved in randomized controlled trials in colorectal or bariatric patients, however there is lack of similar data for laparoscopic liver resection. Doubts about lowering the pneumoperitoneum pressure too hasty are supported by apprehension of worse bleeding control during liver parenchyma transection and its impact on postoperative results.

The aim of the trial is to assess the impact of standard (14 mmHg; arm 1) versus low (10 mmHg; arm 2) pneumoperitoneum pressure on intraoperative blood loss, what will be the primary outcome. As secondary endpoints following outcomes will be measured: quality of operating space, intraoperative adverse events, quality of recovery, postoperative renal function, 30-day postoperative complications rate, length of hospital stay. The investigators assume that lower pneumoperitoneum provides non-inferior blood loss control during laparoscopic liver resection with better postoperative results.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After signing the informed consent patients will be randomized into 2 groups. Randomization will be conducted by investigators via drawing a sealed envelope with computer-generated intervention code at the Department just before patient transfer to the operating theatre. There will be two study arms with 1:1 fashion

For both trial arms additional routine elements of perioperative anesthesia care will be defined:

* low central vein pressure, aimed for 5 ± 2 mmHg with restrictive fluid therapy
* ventilation in a volume-controlled mode without intraoperative high positive end-expiratory pressure (PEEP)
* invasive arterial blood pressure monitoring with maintaining mean arterial pressure ≥ 60 mmHg
* maintaining hemoglobin concentration \> 8g/dl
* maintaining normothermia and normoglycemia
* maintaining oxygenation \>94%, in case of hypercapnia with respiratory acidosis, the respiratory rate and tidal volume will be stepwise increased

The surgeon will be blinded to the study arm and level of pneumoperitoneum pressure.

The blood loss during liver parenchyma transection and total procedure blood loss will be reported based on the amount of sucked outside intraperitoneal fluids after liver transection and after procedure without volume inserted for intraperitoneal irrigation. The estimated blood loss will be measured in milliliters. Patients who are converted to open surgery are excluded from the analysis of the primary end-point.

During the procedure, the surgeon will be asked regularly to rate the quality of operating space in accordance to the Leiden Surgical Rating Scale. In case of inadequate operating space, pneumoperitoneum pressure may be increased by 2 mmHg (with maximum of 16 mmHg in arm 1. and 12 mmHg in arm 2.). Intraoperative adverse events will be assessed in accordance to ClassIntra classification. Quality of recovery (QoR) will be measured on postoperative day 1, 3 and 5 with patient reported QoR-40 questionnaire, 30-day postoperative complication rate will be assessed in accordance to Clavien-Dindo classification. Length of hospital stay will be counted from the date of surgery to the discharge day. All patients will be followed up by researchers who are blinded to the intraoperative grouping.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard pneumoperitoneum pressure

Laparoscopic liver resection performed in standard (14mmHg) pneumoperitoneum pressure

Group Type ACTIVE_COMPARATOR

Pneumoperitoneum 14mmHg

Intervention Type PROCEDURE

Performing surgery in 14mmHg pneumoperitoneum pressure

Low pneumoperitoneum pressure

Laparoscopic liver resection performed in low (10mmHg) pneumoperitoneum pressure

Group Type EXPERIMENTAL

Pneumoperitoneum 10mmHg

Intervention Type PROCEDURE

Performing surgery in 10mmHg pneumoperitoneum pressure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pneumoperitoneum 14mmHg

Performing surgery in 14mmHg pneumoperitoneum pressure

Intervention Type PROCEDURE

Pneumoperitoneum 10mmHg

Performing surgery in 10mmHg pneumoperitoneum pressure

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled to perform elective laparoscopic major liver resection
* Age of 18 years or older
* Signed informed consent

Exclusion Criteria

* Severe cardiopulmonary disease
* Severe renal disease
* Liver cirrhosis
* Emergency surgery
* Pregnancy
* Patient's refusal of participation
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jagiellonian University

OTHER

Sponsor Role collaborator

Regional Oncology Center, Białystok, Poland

UNKNOWN

Sponsor Role collaborator

Medical University of Warsaw

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wacław Hołówko

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wacław Hołówko, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Medical University of Warsaw

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of General, Transplant and Liver Surgery, Medical University of Warsaw

Warsaw, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KB/160/2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.